Weight Loss Drugs Market Size and Forecast 2024-2033| Pfizer Inc., Roche, Merck & Co., AbbVie Inc., Novartis AG

Healthy eating: group of fresh multicolored foods to help lower cholesterol levels and for heart care shot on wooden table. The composition includes oily fish like salmon. Beans like Pinto beans and brown lentils. Vegetables like garlic, avocado, broccoli, eggplant and tomatoes. Fruits like apple, grape, orange and berries. Nuts like almonds and walnuts. Soy products like tofu and soybeans. Cereals and seeds like chia seeds, flax seeds, oatmeal and barley. Olive oil, dark chocolate and yogurt with added sterols and stanols. High resolution 42Mp studio digital capture taken with SONY A7rII and Zeiss Batis 40mm F2.0 CF lens

The Weight Loss Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Weight Loss Drugs Market:

https://www.thebusinessresearchcompany.com/report/weight-loss-drugs-global-market-report

According to The Business Research Company’s Weight Loss Drugs Global Market Report 2024, The weight loss drugs market size has grown exponentially in recent years. It will grow from $1.94 billion in 2023 to $2.87 billion in 2024 at a compound annual growth rate (CAGR) of 47.8%. The growth in the historic period can be attributed to increasing obesity rates, lifestyle changes, awareness and education, early diagnosis of medical conditions, rising healthcare expenditure

The weight loss drugs market size is expected to see exponential growth in the next few years. It will grow to $12.17 billion in 2028 at a compound annual growth rate (CAGR) of 43.5%. The growth in the forecast period can be attributed to increasing geriatric population, social media influence, fitness and wellness trends, cultural perception of beauty, pharmaceutical industry investments. Major trends in the forecast period include technological advancements, focus on non-prescription solutions, personalized medicine, combination therapies, product innovation, post-market surveillance.

Increasing obesity rates is expected to propel the growth of the weight loss drugs market going forward. Obesity rate refers to the proportion of individuals in a population who have a body mass index (BMI) equal to or greater than 30. Weight loss drugs are medications used in obesity to help individuals achieve weight loss by either reducing appetite, increasing feelings of fullness, or interfering with the absorption of nutrients For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government organization, adult obesity rates exceeded 35% in 19 states in 2021 and 22 states in 2022. Further, adult obesity prevalence was at or above 35% in 2022. Further, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, it is estimated that over 4 billion people are expected to be obese by 2035. Therefore, the rise in the increasing obesity rates is driving the growth of the weight loss drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13761&type=smp

The weight loss drugs market covered in this report is segmented –

1) By Type: Liquid, Tablets, Capsules

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Weight-Reducing Aid, Fat Absorption Inhibitors, Metabolic Boosters

Major companies operating in the weight loss drug market are developing innovative products such as Zepbound (tirzepatide) injection to better serve patients. Zepbound is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company received FDA approval for tirzepatide injection (Zepbound) for chronic weight management in adults with overweight or obesity and at least 1 weight-related condition. Zepbound has the potential to be a commercially successful drug, as it is the first and only FDA-approved obesity treatment that activates both GIP and GLP-1 receptors.

The weight loss drugs market report table of contents includes:

1. Executive Summary

2. Weight Loss Drugs Market Characteristics

3. Weight Loss Drugs Market Trends And Strategies

4. Weight Loss Drugs Market – Macro Economic Scenario

5. Global Weight Loss Drugs Market Size and Growth

26. South America Weight Loss Drugs Market

27. Brazil Weight Loss Drugs Market

28. Middle East Weight Loss Drugs Market

29. Africa Weight Loss Drugs Market

30. Weight Loss Drugs Market Competitive Landscape And Company Profiles

Top Major Players: